Regeneron CEO Leonard Schleifer said his company hopes to have its COVID-19 treatment produced and ready for clinical testing possibly by August, reported CNBC.
"We already have tubes with lots of antibodies in them. Over the course of the next weeks we're going to screen them for the best couple that we think could block this virus," he said.
"Then we’re going to use our tricks to immediately get it into scale up and be making 200,000 prophylactic doses by August time frame," the CEO added.
Schleifer said Regeneron would also be pursuing clinical trials and drug manufacturing at once, saying "we can do this in parallel. As soon as we get a green light that it looks good, we'll be able to deploy those large-scale approaches."
Regeneron is developing its drug in agreement with the US Department of Health and Human Services, while Johnson & Johnson, Moderna and Sanofi are also pursuing a treatment for the novel coronavirus.
To read more NewsPoints articles, click here.